Karyopharm Therapeutics (KPTI) Analyst & Key Data

Analyst Consensus

Buy12 analysts

Buy

Updated Sep 12, 2026

Total Analysts12

Buy

13

Hold

5

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$1.61

Median Target+749.07%

$13.67

Potential upside vs current price

Current Stock Price

$1.61

Median Target+749.07%

$13.67

Potential upside vs current price

Analyst Consensus

Buy12 analysts

Buy

Updated Sep 12, 2026

Total Analysts12

Buy

13

Hold

5

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$1.61

Median Target+749.07%

$13.67

Potential upside vs current price

Current Stock Price

$1.61

Median Target+749.07%

$13.67

Potential upside vs current price

Karyopharm Therapeutics Inc.